Coronary Artery Disease Clinical Trials

463 recruitingLast updated: June 18, 2026

There are 463 actively recruiting coronary artery disease clinical trials across 65 countries. Studies span Not Applicable, Phase 4, Phase 2, Phase 3, Phase 1. Top locations include Seoul, South Korea, New York, New York, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Coronary Artery Disease Trials at a Glance

463 actively recruiting trials for coronary artery disease are listed on ClinicalTrialsFinder across 6 cities in 65 countries. The largest study group is Not Applicable with 184 trials, with the heaviest enrollment activity in Seoul, New York, and Barcelona. Lead sponsors running coronary artery disease studies include Fundación EPIC, Seung-Jung Park, and China National Center for Cardiovascular Diseases.

Browse coronary artery disease trials by phase

Treatments under study

About Coronary Artery Disease Clinical Trials

Looking for clinical trials for Coronary Artery Disease? There are currently 412 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Coronary Artery Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Coronary Artery Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 463 trials

Recruiting
Not Applicable

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

Arterial Occlusive DiseasesPainCardiovascular Diseases+12 more
Teleflex1,859 enrolled1 locationNCT07258290
Recruiting
Not Applicable

DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.

Coronary Artery Disease
Fundación EPIC128 enrolled13 locationsNCT06657833
Recruiting

Product Surveillance Registry

Cardiac Rhythm DisordersDigestive disordersMinimally Invasive Surgical Procedures+13 more
Medtronic100,000 enrolled395 locationsNCT01524276
Recruiting

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

Coronary Artery DiseaseIschemic Heart Disease
Fundación EPIC500 enrolled12 locationsNCT06863155
Recruiting
Not Applicable

Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

Coronary Artery Disease
Fundación EPIC2,100 enrolled16 locationsNCT07190690
Recruiting

ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

Coronary Artery Disease
Emory University5,000 enrolled19 locationsNCT07559903
Recruiting
Phase 1

A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease

stable coronary artery diseaseHealthy Volunteers
Hoffmann-La Roche196 enrolled1 locationNCT07495813
Recruiting
Not Applicable

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

Coronary Artery DiseaseInterventional CardiologyMechanical Circulatory Support+1 more
Supira Medical358 enrolled14 locationsNCT07296744
Recruiting

Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI

Coronary Artery Disease
Beth Israel Deaconess Medical Center107 enrolled1 locationNCT05491668
Recruiting
Not Applicable

Effects of Myofascial Release on Cardiac Patients After Median Sternotomy

Coronary Artery Disease (CAD)Valve Heart DiseaseAortic Aneurysm and Dissection
Siou-Pin Huang50 enrolled1 locationNCT07649330
Recruiting

Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes

Pollution; ExposureMicroplasticsNanoplastics+4 more
Azienda Ospedaliera "Sant'Andrea"120 enrolled6 locationsNCT07291609
Recruiting
Not Applicable

PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]

AtherosclerosisCoronary Artery DiseaseCoronary Atherosclerosis of Native Coronary Artery
Johns Hopkins University33 enrolled1 locationNCT05994014
Recruiting
Phase 4

CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

Coronary Artery DiseaseCoronary
West China Hospital233 enrolled1 locationNCT07612774
Recruiting
Phase 3

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

Chronic Coronary SyndromeStable Coronary Artery Disease CAD
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.1,703 enrolled18 locationsNCT07195149
Recruiting

Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography

Chronic Coronary SyndromeAngina, StablePercutaneous Coronary Intervention (PCI)+1 more
Fundacion Investigacion Interhospitalaria Cardiovascular246 enrolled5 locationsNCT07638137
Recruiting

Insights From the FAST-TRACK CABG Trial: a Clinical Outcome Study in Patient With Previous Surgical Revascularization for Complex Three-vessel or Left Main Coronary Artery Disease Based on Coronary Computed Tomography Angiogram, and Fractional Flow Reserve Derived by Computed Tomography

Multivessel Coronary Artery Disease
Centro Cardiologico Monzino100 enrolled1 locationNCT07628270
Recruiting
Not Applicable

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Coronary Artery Disease
Teleflex150 enrolled20 locationsNCT06779630
Recruiting
Not Applicable

Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease

Coronary Artery DiseasePercutaneous Coronary Intervention (PCI)Diffuse Coronary Artery Disease
University Hospital, Geneva150 enrolled3 locationsNCT06710210
Recruiting

Radial Access Data in Vascular Interventions Registry

Peripheral Arterial DiseaseCoronary Artery DiseaseRadial Artery Spasm+2 more
Mersin Medicalpark Hastanesi20,000 enrolled1 locationNCT07614386
Recruiting
Not Applicable

Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial

Coronary Artery DiseaseDrug-eluting StentDrug-eluting Balloon
Translumina GmbH1,380 enrolled1 locationNCT07397845